Immunome Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.9 | $9.0 | $14.0 | — | — |
| Operating income | -$224.1 | -$305.8 | -$109.5 | -$36.9 | -$25.2 |
| Net income | -$212.4 | -$293.0 | -$106.8 | -$36.9 | -$24.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$200.6 | -$118.0 | -$8.4 | -$28.9 | -$18.3 |
Shares outstanding 113.6M · Free float 83.1%
Annual filing data through FY ended December 31, 2025; float as of September 10, 2026.